Eli Lilly and Company $LLY Shares Bought by Bosman Wealth Management LLC

Key Points

• Bosman Wealth Management increased its Eli Lilly position by 30.7% in the third quarter, acquiring 960 additional shares for a total of 4,084 shares valued at approximately $4.725 million. Institutional investors collectively own 82.53% of the company.
• Eli Lilly reported strong third-quarter results, with revenue rising 39% year over year to $24.4 billion and adjusted EPS of $7.48, well above consensus. The company raised its 2026 revenue forecast to $91 billion-$92 billion, supported by robust Mounjaro and Zepbound demand.
• Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and average price target of $1,398.43, but investors face elevated valuation and execution risks, including pricing pressure, one-time earnings benefits and heavy reliance on GLP-1 drugs.

Bosman Wealth Management LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 30.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,084 shares of the company's stock after purchasing an additional 960 shares during the period. Eli Lilly and Company accounts for about 2.9% of Bosman Wealth Management LLC's investment portfolio, making the stock its 10th largest position. Bosman Wealth Management LLC's holdings in Eli Lilly and Company were worth $4,725,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Choreo LLC raised its stake in shares of Eli Lilly and Company by 2.2% in the 3rd quarter. Choreo LLC now owns 30,453 shares of the company's stock valued at $35,237,000 after acquiring an additional 655 shares in the last quarter. Livelsberger Financial Advisory acquired a new stake in Eli Lilly and Company in the 3rd quarter worth approximately $193,000. Fonville Wealth Management LLC lifted its holdings in Eli Lilly and Company by 21.8% in the 3rd quarter. Fonville Wealth Management LLC now owns 358 shares of the company's stock worth $414,000 after purchasing an additional 64 shares during the last quarter. Elwood & Goetz Wealth Advisory Group LLC boosted its position in Eli Lilly and Company by 4.0% during the third quarter. Elwood & Goetz Wealth Advisory Group LLC now owns 964 shares of the company's stock worth $1,116,000 after purchasing an additional 37 shares during the period. Finally, Sage Rhino Capital LLC boosted its position in Eli Lilly and Company by 0.6% during the third quarter. Sage Rhino Capital LLC now owns 2,027 shares of the company's stock worth $2,345,000 after purchasing an additional 13 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
• Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
• Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
• Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

Analysts Set New Price Targets

Several equities analysts have commented on LLY shares. Guggenheim increased their price target on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a "buy" rating in a report on Friday, September 18th. Cantor Fitzgerald upped their price objective on shares of Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the stock an "overweight" rating in a report on Thursday, October 8th. Truist Financial reaffirmed a "buy" rating and set a $1,612.00 price objective (up from $1,376.00) on shares of Eli Lilly and Company in a report on Friday. Leerink Partners raised their target price on shares of Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an "outperform" rating in a research note on Wednesday, October 21st. Finally, Bank of America reissued a "buy" rating and set a $1,497.00 target price on shares of Eli Lilly and Company in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $1,398.43.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president owned 11,875 shares in the company, valued at $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This trade represents a 56.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Trading Up 3.1%

Shares of Eli Lilly and Company stock opened at $1,415.64 on Friday. The company's fifty day simple moving average is $1,197.72 and its 200-day simple moving average is $1,092.57. The company has a market cap of $1.33 trillion, a price-to-earnings ratio of 45.95, a PEG ratio of 1.78 and a beta of 0.46. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 1 year low of $834.19 and a 1 year high of $1,449.68.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts' consensus estimates of $5.71 by $1.77. The business had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 93.68%. The firm's revenue for the quarter was up 38.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $7.02 earnings per share. As a group, sell-side analysts expect that Eli Lilly and Company will post 35.18 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company's dividend payout ratio is presently 22.46%.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.